Business
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
First results of SCENESSE® study expected in 2H 2026Executive summary Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achievedRandomised trial, 20-week treatment protocol plus 6-month follow upStudy sites in North America, Africa and EuropeFirst clinical observations with afamelanotide positive MELBOURNE, Australia, May 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg)
About this update from Clinuvel Pharmaceuticals Limited
[{"type":"image","alt":"Clinuvel Pharmaceuticals Limited","displaySize":"","headline":null,"caption":"Clinuvel Pharmaceuticals Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZGfbstHkppwPJkoYvH5dQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6397a3f79f4dc9eb1683148adb10fab8","width":300,"height":157}},"lazy":false},{"type":"text","content":"First results of SCENESSE® study expected in 2H 2026","length":52,"tagName":"p"},{"type":"text","content":"Executive summary","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Recruitment target of 200 vitiligo patients (Fitzpatrick skin type III-VI) in CUV105 study achieved","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Randomised trial, 20-week treatment protocol plus 6-month follow up","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Study sites in North America, Africa and Europe","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"First clinical observations with afamelanotide positive","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":268,"olType":false},{"type":"text","content":"MELBOURNE, Australia, May 07, 2025 (GLOBE NEWSWIRE) -- CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled. The last patient to enter the study is scheduled to complete screening in May 2025. First results from the study are expected in the second half of 2026.","length":365,"tagName":"p"},{"type":"text","content":"CUV105: first SCENESSE® Phase III vitiligo trial","length":48,"tagName":"p"},{"type":"text","content":"SCENESSE® is being evaluated as a systemic repigmentation therapy for vitiligo patients, with a clinical focus on adolescent (12 years and above) and adult patients with darker skin types (Fitzpatrick III-VI).1","length":210,"tagName":"p"},{"type":"text","content":"CUV105 is a randomised multi-centre Phase III trial being conducted in 37 study sites across three continents. The majority of patients (57%) have been enrolled in the United States. Patients receive treatment with either SCENES...